Hester Biosciences Limited — Results, 30-01-2025: Integrated Filing- Financial

Hester Biosciences has announced a board meeting, resulting in the approval of its unaudited standalone and consolidated financial results for the quarter and nine-month period ending December 31, 2024.

Standalone revenue from operations declined 4% YoY to ₹628.26 crore, while profits fell 31% in Q3 but grew 13% over nine months. Consolidated performance recorded a 6% drop in quarterly sales, yet demonstrated a substantial profit increase of 184% in Q3 due to improved margins and effective cost management.

Investor sentiment may see a positive outlook, driven by strong growth in the Poultry and Petcare divisions and anticipated recovery in Animal Healthcare. Hester's strategic focus on vaccine innovations and market penetration is expected to bolster future performance.